# A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

> **NCT07135349** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Argo Biopharmaceutical Co., Ltd.** · enrollment: 209 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** BW-20507 with/without NUC
- **DRUG:** BW-20507 with/without NUC, Peg-IFNa

## Key facts

- **NCT ID:** NCT07135349
- **Lead sponsor:** Shanghai Argo Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2026-06-07
- **Final completion:** 2028-05-08
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07135349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07135349, "A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07135349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*